医药品·生物科技交易的特许权比率

製药和生物技术项目的特许权费率是一站式来源，提供数百项资本交易的实际交易资讯（许可技术、特许权费率、许可费、预付款、里程碑等）。

本报告提供了最新合作的详细信息，披露了製药、生物技术和诊断领域宣布的特许权使用费率。本报告提供了 692 个合作项目的详细信息，这些项目披露了 2010 年至 2024 年的特许权使用费率。

本报告概述了公司如何以及为何签订合作协议，在化合物或技术商业化时支付特许权使用费。

了解潜在合作伙伴谈判的交易条款的灵活性可以帮助您深入了解谈判过程，了解条款谈判期间的预期结果。许多小型企业希望了解有关付款条件的详细信息，但真正重要的是付款方式 - 合约文件中隐藏着一些在新闻稿或资料库中找不到的见解。

本报告提供了自 2010 年以来宣布的 692 项合作伙伴交易的完整列表，这些交易记录在当前协议交易/合作伙伴关係数据库中，并且我正在定量披露这些交易的特许权使用费。每笔交易的记录和特许权使用费揭露均透过交易线上副本（如果有取得）的连结提供，包括本公司及其合作伙伴向美国证券交易委员会提交的实际合约文件。

主要优势

此报告具有以下优点：

• 忠诚度 了解趋势（自 2010 年以来） < li >使用实际案例研究对特许权使用费条款进行结构分析
• 查看合作伙伴/许可协议：阐明特许权使用费率
• 基准分析：确定交易的市场价值
• 财务条款：一次性付款、里程碑付款、特许权使用费 < li>交易清单：按公司名称 (A-Z)、按处理重点领域、按技术类型
• 获取合约文件：有关交易结构的见解
• 尽职调查：评估合作伙伴公司对拟议合约条款的遵守情况
• 节省数百小时的研究时间

研究范围

• 本报告旨在为读者提供有关版税率趋势和结构的详细资讯世界领先的生命科学公司进行的资本交易。

本报告包??括：

• 2010年以来生物製药行业的特许权使用费趋势 结构分析
• 披露特许权使用费率的真实许可协议案例研究
• 综合清单已揭露许可 费率的许可协议数量（自 2010 年以来） 访问
• 主要许可协议的许可费率和金额（自 2010 年以来）
• 最活跃的许可费率披露（自2010 年以来）

本报告涵盖交易可获得资讯的项目/合约按以下顺序列出：

• 按公司名称（A-Z）
• 按交易金额
• 按处理领域
• 技术类型单独
• 每个交易标题都透过网路连结连结到实际交易记录的线上版本。
• 此报告提供了对许可协议的可用合约文件的全面存取。

藉由实际合约的分析，可得出以下的评估:

• 授予的确切特许权使用费率是多少？
• 合约实际上授予合作伙伴公司什么？
• 授予哪些类型的专有权？
• 合约结算结构是怎么样的？
• 如何审核销售和付款？
• 合约期限是多久？
• 合约的主要条款是如何定义的？
• 智慧财产权的处理和所有权如何？
• 谁负责商业化？
• 谁负责开发、供应和製造？ <一i=54>
• 如何管理保密与揭露？
• 如何解决争议？
• 什么情况下可以取消合约？
• 如果所有者发生变化会怎样？
• 已就何种类型的分授权或分包条款达成协议？
• 公司主张哪些样板条款？
• 哪些样板条款会根据合作伙伴和交易类型的不同而有所不同？
• 公司对契约法主张哪一个管辖权？

目录

第1章 简介

• 什么是版税？
• 特许权使用费历史记录
• 药品和生物技术特许权使用费
• 特许权使用费和收益分成
• 调查概述

第2章 医药品及生物科技的特许权比率概要

• 特许权使用费趋势（2010-2024 年）
• 如何计算收入占有率
• 近期文献回顾
• 未来特许权使用费率

第3章 医药品·生物科技交易的忠诚度(权利金)条款

• 合作协议的结构
• 典型版税条款的结构
• 版税条款范例
  • 个案研究(1)
  • 个案研究 (2) < li>个案研究（3）
  • 个案研究（4）

第四章积极揭露特许权使用费费率的公司

• 最积极揭露特许权使用费的公司费率

第 5 章特许权使用费率协议清单

• 探索特许权使用费率并获得更深入的见解
• 交易清单
• 交易清单：交易特许权使用费率 - 按公司姓名 (A-Z)
• 交易清单：交易中的特许权使用费费率- 按治疗领域
• 交易清单：交易中的特许权使用费率 - 按合约签订时的开发阶段
• 交易清单：按治疗领域划分的特许权使用费率交易 - 按技术类型
• 特许权使用费率参考
• 特许权使用费率交易合约范例 < li>关于 Biopharma Research Ltd
• 当前合作伙伴
• 当前协议
• 当前合作伙伴的最新报告标题

Royalty Rates in Pharmaceutical and Biotechnology Deals is your one-stop source for providing real-deal information on hundreds of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments.

This report provides details of the latest partnering deals which disclose a royalty rate announced in the pharmaceutical, biotechnology and diagnostic sectors. The report provides details of 692 partnering deals disclosing royalty rates from 2010 to 2024.

The report provides an overview of how and why companies enter partnering deals where a royalty is payable upon commercialization of the compound or technology.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of 692 partnering deals announced since 2010 where a quantitative royalty rate has been disclosed, as recorded in the Current Agreements deals and alliances database. Each deal record and royalty disclosure is available in further detail via a link to online copy of the deal including actual contract document, where available, as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of royalty rate trends in pharma and biotech since 2010. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in royalty rates in the pharma and biotech sectors since 2010.

Chapter 3 provides a more detailed insight into the structure of a royalty rate clause and how it fits with the other financial terms of the partnering deal.

Chapter 4 provides an insight into companies active in disclosing royalty rates as well as those deals attracting the highest royalty rates.

Chapter 5 provides comprehensive and detailed access to deals which disclose a royalty rate since 2010 where a contract document is available. Contract documents provide an in-depth insight into the actual deal terms agreed between the parties with respect to the royalty rate.

In addition the report includes a comprehensive deal directory listing of all deals where a royalty rate has been disclosed announced since 2010. Each listing is organized as a directory by company A-Z, stage of development at signing, therapeutic area, and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends in royalty rates in pharma and biotech deal making since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about royalty rates in the pharma and biotech sector.

Key benefits

Royalty Rates in Pharmaceutical and Biotechnology Deals provides the following benefits:

• Understand royalty rate trends since 2010
• Analysis of the structure of royalty clauses with real life case studies
• Browse collaboration and licensing deals which reveal a royalty rate
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Royalty Rates in Pharmaceutical and Biotechnology Deals is intended to provide the reader with an in-depth understanding of the royalty rate trends and structure of deals entered into by leading life science companies worldwide.

Royalty Rates in Pharmaceutical and Biotechnology Deals includes:

• Trends in royalty rates in the biopharma industry since 2010
• Analysis of royalty rate clause structure
• Case studies of real-life licensing deals which disclose royalty rates
• Comprehensive listing of licensing deals which disclose royalty rates since 2010
• Access to licensing contract documents which disclose royalty rates
• The leading licensing deals by royalty rate value since 2010
• Most active royalty rate disclosures since 2010

In Royalty Rates in Pharmaceutical and Biotechnology Deals available deals and contracts are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.
• The Royalty Rates in Pharmaceutical and Biotechnology Deals report provides comprehensive access to available contract documents for licensing deals.

Analyzing actual contract agreements allows assessment of the following:

• What are the precise royalty rates granted?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

• 1.1. What are royalties?
• 1.2. History of royalty rates
• 1.3. Royalties in pharmaceuticals and biotechnology
• 1.4. Royalties versus revenue share
• 1.5. Overview of the report

Chapter 2 - An overview of pharmaceutical and biotechnology royalty rates

• 2.1. Trends in royalty rates 2010 - 2024
• 2.2. How do revenue shares figure?
• 2.3. A review of recent literature
• 2.4. Royalty rates in the future

Chapter 3 - The royalty clause in pharmaceutical and biotechnology deals

• 3.1. Partnering agreement structure
• 3.2. Structure of a typical royalty clause
• 3.3. Example royalty clauses
  • 3.3.1. Case study 1
  • 3.3.2. Case study 2
  • 3.3.3. Case study 3
  • 3.3.4. Case study 4

Chapter 4 - Companies actively disclosing royalty rates

• 4.1. Most active companies in disclosing royalty rates

Chapter 5 - Royalty rate contract directory

• Explore royalty rates within the deal contract document to gain greater insight
• Deal Directory
• Deal Directory - Royalty rates in deals - by company A-Z
• Deal Directory - Royalty rates in deals - by therapy area
• Deal Directory - Royalty rates in deals - by stage of development at signing
• Deal Directory - Royalty rates in deals - by technology type
• Royalty rate references
• Example royalty rate deal contract document
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Trends in pharma and biotech royalty rates, 2010 - 2024
• Figure 2: Components of the partnering deal structure
• Figure 3: Components of the partnering royalty clause
• Figure 4: Most active companies disclosing royalty rate 2010 - 2024
• Figure 5: Licensing agreement for rhAAT - rEVO Biologics, LFB Biotechnologies